Peripheral neuropathy is one of the most frequent and debilitating adverse effects encountered by patients with cancer undergoing chemotherapy treatment. For multiple myeloma (MM), every effective regimen includes at least one agent that can cause neuropathy, a major dose-limiting toxicity in clinical trials and in clinical practice. Furthermore, neuropathy occurs even before therapy as a consequence of the disease in approximately 20% of patients with MM, and can even occur in the precursor condition, monoclonal gammopathy of undetermined significance.


Becker p. et al.

J Clin Oncol. 2011 Mar 1;29(7):783-6. doi: 10.1200/JCO.2010.33.4771. Epub 2011 Jan 18.

Click here to view Article

Tagged with →